Last reviewed · How we verify
Ophthalmic Emulsion
Ophthalmic Emulsion is a Artificial tear / Ocular lubricant Small molecule drug developed by Allergan. It is currently FDA-approved for Dry eye disease / Keratoconjunctivitis sicca.
An ophthalmic emulsion that lubricates and protects the ocular surface by providing moisture and forming a protective barrier on the cornea and conjunctiva.
Ophthalmic Emulsion is a small molecule formulation used to treat various eye conditions, including Pterygium, Dry Eye Syndrome, Ocular Discomfort, Open-Angle Glaucoma or Ocular Hypertension, and Ocular Surface Disease. It is available in different concentrations, including 0.1%, and has been studied in clinical trials, such as NCT05456425, for its safety and efficacy.
At a glance
| Generic name | Ophthalmic Emulsion |
|---|---|
| Sponsor | Allergan |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ophthalmic emulsions are oil-in-water or water-in-oil formulations designed to deliver sustained lubrication to dry eyes. They work by coating the ocular surface, reducing tear evaporation, and providing comfort through prolonged contact time. These formulations are particularly effective for moderate to severe dry eye disease where aqueous tear deficiency or meibomian gland dysfunction is present.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
Common side effects
- Blurred vision
- Eye irritation
- Foreign body sensation
- Ocular discomfort
Key clinical trials
- Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses (PHASE2)
- Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks (PHASE4)
- Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure (PHASE2)
- Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis (PHASE2)
- Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA) (NA)
- Optimizing the Ocular Surface With Systane COMPLETE Pre- and Post-operatively in Patients With Dry Eye Planning for Cataract Surgery: An Extension Study of Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery (PHASE4)
- A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium (PHASE3)
- 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ophthalmic Emulsion CI brief — competitive landscape report
- Ophthalmic Emulsion updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about Ophthalmic Emulsion
What is Ophthalmic Emulsion?
How does Ophthalmic Emulsion work?
What is Ophthalmic Emulsion used for?
Who makes Ophthalmic Emulsion?
What drug class is Ophthalmic Emulsion in?
What development phase is Ophthalmic Emulsion in?
What are the side effects of Ophthalmic Emulsion?
Related
- Drug class: All Artificial tear / Ocular lubricant drugs
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Dry eye disease / Keratoconjunctivitis sicca
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing